Previous 10 | Next 10 |
Amneal Pharmaceuticals (AMRX) posted first-quarter revenue that fell short of Wall Street estimates, partly hurt by decreased influenza activity during the period, and maintained its full-year forecast.Revenue during the quarter fell 1% to $493.1M, due to the higher customer pu...
Amneal Pharmaceuticals (AMRX): Q1 Non-GAAP EPS of $0.20 beats by $0.02; GAAP EPS of $0.04 misses by $0.03.Revenue of $493.1M (-1.1% Y/Y) misses by $19.59M.Press Release For further details see: Amneal Pharmaceuticals EPS beats by $0.02, misses on revenue
‒ Q1 2021 Net Revenue of $493 million; GAAP Net Income of $7 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.20 ‒ ‒ Maintaining 2021 Full Year Financial Ou...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time...
Amneal Pharmaceuticals, Inc. (the “ Company ”) (NYSE: AMRX) and Kashiv BioSciences LLC (“ Kashiv ”) today announced that Amneal Pharmaceuticals LLC (“ Amneal ”), a subsidiary of the Company, has completed its previously announced acq...
Not your typical March as the month came 'in like a lamb, and out like a lion.' No, we aren’t discussing precipitation in March, but the precipitous equity market behavior for the U.S stock market on the precipice of all-time highs and what that means for the top stocks moving into Apr...
Today, we take our first look at a small developmental biotech concern named Amneal Pharmaceuticals. The company came public in the first half of 2018 and is deep in "Busted IPO" territory. The shares have become a battleground stock within the analyst community. A full analys...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q4 2020 Earnings Call Feb 26, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call Transc...
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Conference Call February 26, 2021 8:30 AM ET Company Participants Tasos Konidaris - Chief Financial Officer Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Joe Todisco - Chief Commercial Officers of Gener...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...